HIV/AIDS Prevention

Data published online suggesting potential HIV prevention in mice

Published in Vaccine Weekly, May 18th, 2005

The Immune Response Corporation (IMNR), a biopharmaceutical immune-based therapy company in the areas of in HIV and multiple sclerosis, announced a preclinical study demonstrating the potential for a gp120-deleted HIV-1 antigen, a component of Remune, with a CpG oligonucleotide adjuvant to have a protective role when administered to Trimera mice prior to HIV infection challenge.

The results of this study in mice were published by the FASEB Journal online.

"This publication tends to validate the animal model and the potential for an HIV-1 antigen as a preventive therapy. While this is very exciting research, it is too early to make comparisons...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-05-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry